RGRX
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2023 Q1 | -0.00 | $19,190 | -$189,333 |
| 2022 Q4 | -0.00 | $19,190 | -$187,519 |
| 2022 Q3 | -0.00 | $19,190 | -$228,239 |
| 2022 Q2 | -0.00 | $19,191 | -$218,656 |
| 2022 Q1 | -0.00 | $19,191 | -$306,304 |
| 2021 Q4 | -0.00 | $19,190 | -$291,782 |
| 2021 Q3 | -0.00 | $19,190 | -$430,643 |
| 2021 Q2 | -0.00 | $19,191 | -$25,537 |